MeiraGTx Holdings (MGTX) just posted its FY 2025 third quarter numbers, with revenue at US$0.4 million and a basic EPS loss of US$0.62, alongside net income excluding extra items of a US$50.5 million loss. Over recent quarters, the company has seen revenue move from US$21.4 million in Q4 2024 to US$3.7 million in Q2 2025, while quarterly basic EPS has tracked between a loss of US$0.48 and US$0.76. This sets the backdrop for the current trailing twelve month loss of US$168.7 million on US$27.4 million of revenue. For investors, this mix of modest top line and sizable losses points to compressed margins and puts the focus on how and when the cost base can be brought under control.

See our full analysis for MeiraGTx Holdings.

With the headline figures set, the next step is to see how these results line up with the prevailing market narratives about MeiraGTx Holdings and where the data challenges those stories.

US$50.5m loss on just US$0.4m revenue

• In Q3 FY 2025, MeiraGTx reported total revenue of US$0.4 million against a net income loss excluding extra items of US$50.5 million, indicating that operating and other costs were far larger than the current revenue base.
• Bears often focus on this kind of pattern, and over the trailing twelve months the company recorded a loss of US$168.7 million on US$27.4 million of revenue, which critics highlight as reinforcing the view that MeiraGTx is still heavily in investment mode rather than close to break even.
  • Losses have grown at about 16.8% per year over the past five years, and the company is not forecast to be profitable over the next three years. This supports the bearish argument about a prolonged loss making phase.
  • With negative shareholders’ equity flagged as a major risk, skeptics point to the combination of recurring large losses and a thin equity base as a key part of their cautious stance.

Stay grounded in the full cautious case before making any decisions about a gene therapy name like this. Then review the detailed bear case for how extended losses and balance sheet pressure could play out 🐻 MeiraGTx Holdings Bear Case.

51.2% forecast revenue growth vs US market 10.4%

• Revenue is forecast to grow at about 51.2% per year, compared with a 10.4% per year forecast for the broader US market, so expectations for MeiraGTx’s top line are much higher than average even though the latest reported quarter only showed US$0.4 million of revenue.
• Supporters of a more optimistic or balanced view often point to this faster expected growth, and the trailing twelve month revenue of US$27.4 million, as the foundation of a bullish narrative that the business could scale into its cost base over time, even if that is not yet reflected in current profitability.
  • What stands out is that forecasts still do not show a move to profit within the next three years, so the strong growth expectations sit alongside ongoing losses rather than a clear path to positive earnings in the data provided.
  • Investors who lean bullish may see the 51.2% forecast growth as a reason to keep watching the story, but the five year loss growth rate of 16.8% highlights that execution on margins will be a central test of that thesis.

P/S of 22.1x vs biotech peers at 7.3x

• MeiraGTx is trading on a P/S of 22.1x compared with the US biotechs industry average of 10.8x and a peer average of 7.3x, so investors are currently paying a higher multiple of revenue for MGTX than for many comparable names.
• Some investors argue this elevated multiple only makes sense if the strong 51.2% forecast revenue growth and eventual progress toward profitability materialize, and the contrast between the current share price of US$7.53 and a single analyst price target of US$26.50 shows that expectations can vary widely when losses, negative equity and high growth forecasts all sit together.
  • On one hand, the higher P/S multiple lines up with the faster expected revenue growth relative to the broader US market at 10.4%, which can support the view that investors are already pricing in rapid expansion.
  • On the other hand, the combination of a trailing twelve month loss of US$168.7 million and negative shareholders’ equity means any stumble in revenue delivery could affect how comfortable the market is with paying a premium multiple over industry and peer averages.

If you want a more balanced read on how other investors are weighing these premium multiples against the loss profile and growth forecasts, it is worth seeing how the wider community frames the trade off in their narratives 📊 Read the what the Community is saying about MeiraGTx Holdings..

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on MeiraGTx Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Mixed messages in the numbers and narratives so far? Take a closer look at the figures, pressure test both sides, and then weigh the company’s balance of risks and potential upsides for yourself by checking the 1 key reward and 2 important warning signs

Explore Alternatives

MeiraGTx Holdings combines a US$168.7 million trailing twelve month loss, negative shareholders’ equity and a premium 22.1x P/S, which highlights pressures on its balance sheet and risk profile.

If that mix of large ongoing losses and thin equity makes you uneasy, consider shifting some attention toward companies screened for stronger financial footing and resilience through the solid balance sheet and fundamentals stocks screener (39 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.